156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

C. Domergue(Institut de Cancérologie de l'Ouest), Anne Patsouris(Institut de Cancérologie de l'Ouest), E. Martin(Institut de Cancérologie de l'Ouest), Paule Augereau(Institut de Cancérologie de l'Ouest), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Mario Campone(Institut de Cancérologie de l'Ouest), Pascal Jézéquel(Institut de Cancérologie de l'Ouest), Claude Lemarié(Inserm)
Annals of Oncology
September 1, 2021
10.1016/j.annonc.2021.08.437
Cited by 3

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410